Example 2 - Colon Cancer Mortality in Iowa Sample Clauses

Example 2 - Colon Cancer Mortality in Iowa. Colon cancer mortality data in Iowa is used to further study the performance of the Bayesian extended AAPC model in estimating cancer mortality rates. Since the most colon cancer death is associated with older population, I limit the study population with the age 50 or above. The age group use five years interval and eight age groups are reported (50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+). The calendar period is chosen from 1981 to 2007. The 2010 SEER program provides cancer mortality data in three years intervals. Eight period groups are reported (1981-1983, 1984-1986, 1987-1989, 1990-1992, 1993-1995, 1996- 1998, 1999-2002, 2003-2007). Table 5.4 describes age and period specific rates (x100,000) and number of cases. Figure 5.7 displays Iowa colon cancer mortality rate in 1981-2007 at each county level for population at age 50 or more. Moolgavkar’s TSCE carcinogenesis model is used to update the age effect in the AAPC model for colon cancer since Armitage-Doll model only consider the age group from 25 to 74. Figure 5.8 displays the distribution of unstructured spatial effects for colon cancer mortality county-wide in Iowa. At those remote counties especially in south and west, we Table 5.4: Age-period specific mortality rates (×100,000) and number of deaths. Colon cancer, Iowa, 1981-2007 Period Age 1981—1983 1984—1986 1987—1989 1990—1992 1993—1995 1996—1998 1999—2002 2002—2007 50-54 24.38 (101) 27.23 (104) 25.18 (95) 21.62 (85) 13.78 (59) 18.71 (88) 15.27 (113) 11.84 (123) 55-59 38.52 (164) 43.80 (178) 38.01 (143) 37.11 (136) 37.10 (141) 31.20 (124) 25.10 (144) 19.79 (173) 60-64 62.33 (251) 50.34 (200) 56.88 (220) 50.07 (190) 57.36 (208) 47.34 (170) 35.13 (170) 32.77 (219) 65-69 89.65 (322) 82.32 (299) 72.65 (266) 68.20 (247) 73.51 (259) 75.15 (251) 65.72 (279) 52.63 (288) 70-74 120.95 (361) 117.50 (358) 110.17 (341) 97.31 (308) 91.47 (291) 96.67 (301) 80.27 (328) 69.92 (334) 75-79 160.88 (375) 166.54 (402) 148.64 (373) 142.12 (366) 135.30 (357) 124.84 (336) 115.87 (419) 101.96 (442) 80-84 212.24 (343) 212.88 (357) 205.07 (358) 199.40 (362) 194.78 (367) 176.34 (344) 152.81 (417) 136.45 (477) 85+ 287.82 (416) 265.32 (408) 282.39 (455) 276.29 (467) 260.94 (465) 270.67 (507) 235.43 (625) 215.35 (789) observe higher spatial effects in estimating the colon cancer mortality rates. Part of the reasons are due to the lack of colorectal cancer screening. Cancer statistics show that the survival rate is high if the colon cancer is diagnosed early [ACS, 2...
Sample 1
AutoNDA by SimpleDocs

Related to Example 2 - Colon Cancer Mortality in Iowa

  • Benefit Level Two Health Care Network Determination Issues regarding the health care networks for the 2017 insurance year shall be negotiated in accordance with the following procedures:

  • STATEWIDE ACHIEVEMENT TESTING When CONTRACTOR is an NPS, per implementation of Senate Bill 484, CONTRACTOR shall administer all Statewide assessments within the California Assessment of Student Performance and Progress (“CAASP”), Desired Results Developmental Profile (“DRDP”), California Alternative Assessment (“CAA”), achievement and abilities tests (using LEA-authorized assessment instruments), the Fitness Gram with the exception of the English Language Proficiency Assessments for California (“ELPAC”) to be completed by the LEA, and as appropriate to the student, and mandated by XXX xxxxxxxx to LEA and state and federal guidelines. CONTRACTOR is subject to the alternative accountability system developed pursuant to Education Code section 52052, in the same manner as public schools. Each LEA student placed with CONTRACTOR by the LEA shall be tested by qualified staff of CONTRACTOR in accordance with that accountability program. XXX shall provide test administration training to CONTRACTOR’S qualified staff. CONTRACTOR shall attend LEA test training and comply with completion of all coding requirements as required by XXX.

  • Power Factor Design Criteria (Reactive Power A wind generating plant shall maintain a power factor within the range of 0.95 leading to 0.95 lagging, measured at the Point of Interconnection as defined in this LGIA, if the ISO’s System Reliability Impact Study shows that such a requirement is necessary to ensure safety or reliability. The power factor range standards can be met using, for example without limitation, power electronics designed to supply this level of reactive capability (taking into account any limitations due to voltage level, real power output, etc.) or fixed and switched capacitors if agreed to by the Connecting Transmission Owner for the Transmission District to which the wind generating plant will be interconnected, or a combination of the two. The Developer shall not disable power factor equipment while the wind plant is in operation. Wind plants shall also be able to provide sufficient dynamic voltage support in lieu of the power system stabilizer and automatic voltage regulation at the generator excitation system if the System Reliability Impact Study shows this to be required for system safety or reliability.

  • Power Factor Design Criteria Developer shall design the Large Generating Facility to maintain an effective power delivery at demonstrated maximum net capability at the Point of Interconnection at a power factor within the range established by the Connecting Transmission Owner on a comparable basis, until NYISO has established different requirements that apply to all generators in the New York Control Area on a comparable basis. The Developer shall design and maintain the plant auxiliary systems to operate safely throughout the entire real and reactive power design range. The Connecting Transmission Owner shall not unreasonably restrict or condition the reactive power production or absorption of the Large Generating Facility in accordance with Good Utility Practice.

  • Orientation and In-Service Program The Hospital recognizes the need for a Hospital Orientation Program of such duration as it may deem appropriate taking into consideration the needs of the Hospital and the nurses involved.

  • Workplace Safety Insurance Benefits (WSIB) Top Up Benefits If the employee is in a class of employees that, on August 31, 2012, was entitled to use unused sick leave credits for the purpose of topping up benefits received under the Workplace Safety and Insurance Act, 1997;

  • PREGNANCY LEAVE BENEFITS Common Central Provisions a) The Employer shall provide for permanent and long-term occasional teachers and teachers hired into a term position who access such leaves, a SEB plan to top up their E.I.

  • Training Designation Type Code Select and insert the appropriate training credit designation type code: Code Short Description Long Description (If Applicable) 01 Undergraduate Credit N/A 02 Graduate Credit N/A 03 Continuing Education Unit N/A 04 Post Graduate Credit N/A 05 N/A N/A

  • PRESCRIPTION MEDICATION BENEFITS, LIMITATIONS AND EXCLUSIONS The following items are limited or excluded from your Prescription Medication coverage:

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

Time is Money Join Law Insider Premium to draft better contracts faster.